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DBackground: Despite the widespread use of transcatheter aortic valve implantation (TAVI), the role of sex on
outcome after TAVI or surgical aortic valve replacement (AVR) has been poorly investigated. We investigated
the impact of sex on outcome after TAVI or AVR.
Methods: There were 2108 patients undergoing TAVI or AVR who were enrolled in the Italian Observational
Multicenter Registry (OBSERVANT). Thirty-day mortality, major periprocedural morbidity, and transprosthetic
gradients were stratified by sex according to interventions.
Results: Female AVR patients showed a worse risk profile compared with male AVR patients, given the higher
mean age, prevalence of frailty score of 2 or higher, New York Heart Association class of 3 or higher, lower body
weight, and preoperative hemoglobin level (P .02). Similarly, female TAVI patients had a different risk profile
than male TAVI patients, given a higher age and a lower body weight and preoperative hemoglobin level
(P  .005), but with a similar New York Heart Association class, frailty score, EuroSCORE (P ¼ NS), a better
left ventricular ejection fraction and a lower prevalence of left ventricular ejection fraction less than 30%, por-
celain aorta, renal dysfunction, chronic obstructive pulmonary disease, arteriopathy, and previous cardiovascular
surgery or percutaneous coronary intervention (P  .01). Women showed a smaller aortic annulus than men in
both populations (P<.001). Female sex was an independent predictor in the AVR population for risk-adjusted
30-day mortality (odds ratio [OR], 2.34; P ¼ .043) and transfusions (OR, 1.47; P ¼ .003), but not for
risk-adjusted acute myocardial infarction, stroke, vascular complications, permanent atrioventricular block
(P ¼ NS). Female sex was an independent predictor in the TAVI population for risk-adjusted major vascular
complications (OR, 2.92; P ¼ .018) and transfusions (OR, 1.93; P ¼ .003), but proved protective against
moderate to severe postprocedural aortic insufficiency (P ¼ .018).
Conclusions: Female sex is a risk factor for mortality after aortic valve replacement, for major
vascular complications after TAVI, and for transfusions after both approaches. (J Thorac Cardiovasc Surg
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The Journal of Thoracic and CarTranscatheter aortic valve implantation (TAVI) has been
reported as an effective treatment option for severe aortic
stenosis in patients at high risk for current surgical aortic
valve replacement (AVR).1 However, few studies have
investigated the impact of sex-related differences on peri-
procedural outcomes after TAVI, although the role of sex
on short- and long-term outcome after cardiac surgery has
been addressed extensively and female sex has been shown
as a risk factor for perioperative mortality in both the
EuroSCORE and Society of Thoracic Surgeons Risk
Score.2,3 As far as TAVI is concerned, contradictory
results have been reached: some investigators have shown
improved survival in female patients after TAVI,1,4,5 other
investigators have found an increased risk for major
vascular complications together with a higher rate of
blood transfusions.6 These studies, however, came from
retrospective analyses of single-center experiences.4-6diovascular Surgery c Volume 147, Number 5 1529
Abbreviations and Acronyms
AV ¼ atrioventricular
AVR ¼ aortic valve replacement
LVEF ¼ left ventricular ejection fraction
NYHA ¼ New York Heart Association
OBSERVANT ¼ Observational Study of
Appropriateness, Efficacy, and
Effectiveness of AVR-TAVI
procedures for the treatment of
severe symptomatic aortic stenosis
OR ¼ odds ratio
PARTNER ¼ Pivotal Placement of Aortic
Transcatheter trial
TAVI ¼ transcatheter aortic valve
implantation
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DTherefore, the aim of this study was to investigate the role
of sex on both clinical presentation and postprocedural
outcomes after TAVI and AVR. The analysis was performed
from a prospective series of patients enrolled in the Italian
National Institute of Health Observational Multicenter
Registry (Observational Study of Appropriateness, Effi-
cacy, and Effectiveness of AVR-TAVI procedures for
the treatment of severe symptomatic aortic stenosis
[OBSERVANT]), a prospective registry aimed at evalua-
ting the efficacy and effectiveness of TAVI versus AVR
procedures for the treatment of severe symptomatic aortic
stenosis.METHODS
Study Design and Data Collection
In December 2010, the Italian National Health Institution in cooperation
with the Italian Ministry of Health, the National Agency for Regional
Health Services, Italian regions, and Italian scientific societies representing
the professionals involved in the management of patients with severe aortic
stenosis launched OBSERVANT.7 Enrollment started in January 2011 and
ended in June 2012. However, the present analysis refers to the first 6
months of OBSERVANT data collection. The study protocol was approved
by the local ethics committees. All patients enrolled in the database
provided informed consent in an anonymous form. A detailed description
of the study protocol has been reported previously.7
Study Population
On the basis of established criteria, the study included all symptomatic
adult patients admitted to hospitals with a diagnosis of severe symptomatic
aortic stenosis (defined as an aortic valve area<1 cm2, a maximum aortic
velocity>4 m/s, or a mean pressure gradient>40 mmHg) and requiring an
aortic valve procedure.7 Treatment allocation always came from the review
of the local multidisciplinary heart team involving cardiologists, surgeons,
and anesthesiologists, as per current guidelines.8
Because of the observational nature of the registry, there was no
standardization of clinical protocols: accordingly, techniques for TAVI
and AVR were left to the discretion of each participating center. Each
interventional team could choose to implant 1 of the 2 commercially1530 The Journal of Thoracic and Cardiovascular Suravailable valves: the balloon-expandable Edwards Sapien or Sapien XT
prosthesis (Edwards Lifesciences, Irvine, Calif) or the self-expandable
CoreValve (Medtronic, Minneapolis, Minn). Sapien devices were
implanted by either the transfemoral or transapical route, and CoreValve
devices were implanted by the transfemoral or transaxillary approach.
Antiplatelet regimens and anticoagulation protocols similarly were based
on individual institutional policies. Surgery, management of cardiopulmo-
nary bypass, cardioplegic techniques, and anesthetic techniques were all
left to each individual center’s discretion, although they were based on
well-established institutional policies.7
End Points and Follow-up Evaluation
Overall hospital mortality was the primary end point of the
OBSERVANT study, whereas secondary end points included overall
mortality within 12 and 24 months and the incidence of in-hospital major
adverse cardiac and cerebrovascular events, as already reported.7
For the purpose of this study, differences in preoperative characteristics
between women and men in both TAVI and AVR populations were
investigated. Hospital mortality was considered the primary end point
and was stratified by sex according to interventions. Acute myocardial
infarction, stroke, major cardiovascular complications, transfusions, per-
manent atrioventricular (AV) block, and transprosthetic gradients were
secondary end points and similarly stratified by sex according to interven-
tions.7 Definitions of end points already have been reported.7 End points
were adjudicated by 2 independent investigators at each participating
center.
Statistical Analysis
All the analyses were performed stratifying by type of intervention
and sex.
Continuous variables are presented as mean  standard deviations and
were compared by the Student t test; categoric variables are presented as
counts and percentages and were compared by the chi-square test or the
Fisher exact test when appropriate. The unadjusted effects of sex on
periprocedural outcomes and 30-day mortality were estimated by univari-
ate logistic regression models for dichotomous outcomes and by linear
regression models for continuous outcomes. For each considered end point
a specific stepwise procedure was used to identify the independent predic-
tors (exclusion probability, 0.10; inclusion probability, 0.20). Sex was used
as the determinant, whereas all the measured potential confounders, includ-
ing variables related to the multicenter nature of the study (ie, volume of
cases by center, surgeon experience, management of anesthesiology/sur-
gery/percutaneous procedures), were offered to the model as independent
variables. For each considered end point a specific multivariable logistic
regression or linear regression model was implemented using age plus
the variables selected by the stepwise procedures. Risk-adjusted odds
ratio (OR) or exponentiation of the beta coefficient (dependent variable
variation in women vs men) and corresponding P values are presented
for AVR and TAVI separately. Intercorrelation between independent
variables was checked with appropriate tests, and co-linearity was avoided
by selecting the most relevant variable (based on statistical and clinical
considerations) between 2 co-linear variables.
All the analyses were performed using the statistical package STATA
version 11 (Stata Corp, College Station, Tex). A P value less than .05
was considered significant.RESULTS
Population Enrolled and Participating Centers
A total of 101 centers (60 cardiac surgery units and 41
catheter laboratories) participate in the registry. Between
January 2011 and June 2011 the population comprised
2108 patients, 1383 (65.6%) of whom underwent surgicalgery c May 2014
TABLE 1. Demographics, clinical characteristics, and angiographic and echocardiographic data by sex and type of intervention
Characteristics
AVR (N ¼ 1383) n (%) TAVI (N ¼ 725) n (%)
Men (N ¼ 768) Women (N ¼ 615) P value Men (N ¼ 297) Women (N ¼ 428) P value
Age (year)* 70.9  9.9 74.2  8.6 <.001 81.1  6.6 82.4  6.3 .005
Weight (kg)* 80.1  18.7 70.6  17.6 <.001 74.5  17.0 67.6  16.5 <.001
Diabetes 198 (25.8) 148 (24.1) .920 76 (25.6) 103 (24.1) .913
Current smoking 255 (33.2) 60 (9.8) <.001 79 (26.6) 23 (5.4) <.001
Creatinine level (mg/dL)* 1.2  1.0 0.9  0.6 <.001 1.3  1.0 1.1  0.6 .002
Chronic dialytic treatment 16 (2.1) 8 (1.3) .777 9 (3.0) 3 (0.7) .199
Albumin level (mg/dL)* 3.5  1.1 3.5  1.1 .771 3.4  0.9 3.5  0.8 .221
Hemoglobin level (mg/dL)* 13.0  1.8 12.1  1.5 <.001 11.8  1.7 11.4  1.5 .001
Active endocarditis 10 (1.3) 1 (0.2) .112 0 (0.0) 1 (0.2) .844
Previous AMI 36 (4.7) 11 (1.8) .060 7 (2.4) 13 (3.0) .929
Unstable angina 47 (6.2) 25 (4.1) .558 17 (5.7) 11 (2.6) .194
COPD 86 (11.2) 57 (9.3) .699 107 (36.0) 102 (23.9) .010
Oxygen dependency 14 (1.8) 4 (0.6) .379 26 (8.7) 29 (6.8) .779
Neurologic dysfunction 10 (1.3) 17 (2.8) .277 29 (9.8) 25 (5.8) .360
Chronic liver disease 12 (1.6) 10 (1.6) 1.0 14 (4.7) 8 (1.9) .280
Active neoplastic disease 13 (1.7) 5 (0.8) .716 14 (4.7) 11 (2.6) .597
Peripheral arteriopathy 119 (15.5) 56 (9.1) .001 87 (29.3) 74 (17.3) .004
Previous cardiac surgery 39 (5.1) 19 (3.1) .476 74 (24.9) 39 (9.1) <.001
Previous vascular surgery 19 (2.5) 5 (0.8) .229 26 (8.7) 11 (2.3) .007
Porcelain aorta 4 (0.5) 0 (0.0) .447 29 (9.8) 25 (5.8) .003
Difficult thoracic approach 1 (0.1) 1 (1.2) .928 9 (3.0) 13 (3.0) .954
Frailty score
2 (partially self-sufficient) 30 (3.9) 37 (6.3) <.001 48 (16.2) 106 (24.8) .096
3 (non–self-sufficient) 1 (0.1) 4 (0.6) 3 (1.0) 4 (0.9)
Previous PCI 76 (9.9) 19 (3.1) <.001 95 (32.0) 87 (20.4) .010
Previous aortic balloon plasty 7 (0.9) 3 (0.5) .813 34 (11.4) 64 (15.0) .709
Critical preoperative state 26 (3.4) 9 (1.5) .271 18 (6.1) 18 (4.2) .813
NYHA class
III 151 (19.7) 165 (26.9) .020 129 (43.4) 192 (45.0) .490
IV 38 (4.9) 29 (4.7) 41 (13.8) 66 (15.5)
EuroSCORE* 5.9  7.6 6.4  6.4 .238 15.9  16.1 14.6  12.0 .239
EuroSCORE>20 37 (4.8) 19 (3.1) .016 57 (19.2) 74 (17.3) .166
Angiographic and echocardiographic findings
Coronary artery disease
1 vessel 114 (14.8) 72 (11.7) <.001 66 (22.2) 75 (18.1) <.001
2 vessels 81 (10.5) 47 (7.6) 15 (5.1) 22 (5.2)
3 vessels 79 (10.3) 25 (4.1) 33 (11.1) 13 (3.0)
Left main 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0)
Mitral valve regurgitation
Mild 351 (45.7) 268 (43.6) .010 158 (53.2) 207 (48.5) .508
Moderate 72 (9.4) 96 (15.6) 67 (22.6) 108 (25.3)
Severe 9 (1.2) 8 (1.3) 6 (2.0) 19 (4.4)
LVEF (%)* 55.5  10.9 58.1  8.5 <.001 48.2  12.6 53.1  11.4 <.001
LVEF,<30 22 (2.9) 2 (0.3) .009 29 (9.8) 13 (3.0) .005
Aortic valve pattern
Valve area (cm2)* 0.8  0.3 0.7  0.3 <.001 0.7  0.3 0.6  0.2 <.001
Peak gradient (mm Hg)* 78.8  22.6 87.4  23.8 <.001 79.0  24.5 83.8  21.7 .008
Mean gradient (mm Hg)* 48.5  14.3 54.3  15.8 <.001 48.4  15.3 51.8  14.7 .003
Annulus diameter (cm)* 22.6  2.2 20.9  1.9 <.001 23.0  2.1 21.3  1.8 <.001
AMI, Acute myocardial infarction; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; NYHA, New York Heart Association; LVEF, left
ventricular ejection fraction. *Variables are presented as mean  standard deviation.
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DAVR, and 725 (34.4%) underwent TAVI. Perioperative data
were 100% completed, whereas follow-up data were
95.8% completed for the AVR population and 95.9%The Journal of Thoracic and Carcompleted for the TAVI cohort. Women represented
59.0% (428 of 725) of the TAVI population and 44.4%
(615 of 1383) of the AVR population.diovascular Surgery c Volume 147, Number 5 1531
TABLE 2. Procedural characteristics by sex and type of intervention
Characteristics
AVR (N ¼ 1383) n (%) TAVI (N ¼ 725) n (%)
M (N ¼ 768) F (N ¼ 615) P value M (N ¼ 297) F (N ¼ 428) P value
Urgency status
Elective 749 (97.5) 596 (97.1) .632 286 (96.3) 413 (96.7) .805
Urgent 10 (1.3) 15 (2.4) 10 (3.4) 10 (2.3)
Emergent 3 (0.4) 1 (0.2) 1 (0.3) 4 (0.9)
Associated coronary procedure 214 (27.9) 113 (18.4) .001 14 (4.7) 24 (5.6) .841
Approach site
Femoral — — — 226 (76.1) 335 (78.4) .858
Iliac — — 0 (0.0) 0 (0.0)
Axillary — — 16 (5.4) 17 (4.0)
Transapical — — 54 (18.2) 69 (16.7)
Type of valve used
CV — — — 173 (58.2) 200 (46.8) .032
ELS — — 124 (41.7) 227 (52.9)
CV, CoreValve; ELS, Edwards Lifesciences Sapien valve.
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DDifferences in AVR Population According to Sex
Female AVR patients showed different baseline charac-
teristics compared with male AVR patients, such as lower
body weight, serum creatinine level, history of smoking,
previous percutaneous coronary intervention, peripheral
arteriopathy, and prevalence of EuroSCORE greater than
20, but also a higher mean age at intervention, lower
baseline hemoglobin level, higher frailty score of 2 to
3, and New York Heart Association (NYHA) class III/IV
(Table 1).
Preoperative angiography and/or echocardiography
showed a better mean left ventricular ejection fraction
(LVEF), a lower prevalence of LVEF less than 30%,
a higher prevalence of moderate to severe mitral regurgita-
tion, higher transaortic mean and peak gradients, and lower
aortic valve area and annular diameters in women;
however, associated coronary artery disease was less
frequent (Table 1), which therefore resulted in a less
common need for an associated coronary artery bypass graft
(Table 2).Differences in TAVI Population According to Sex
The TAVI population also showed significant differences
in baseline characteristics according to sex: in particular,
despite a higher mean age at intervention, a lower body
weight, and a lower preoperative hemoglobin level, female
TAVI patients had a lower history of smoking and chronic
obstructive pulmonary disease, serum creatinine level,
peripheral arteriopathy, porcelain aorta, previous cardiac
and vascular surgery, and previous percutaneous coronary
intervention (Table 1). Associated coronary artery disease
was similarly less common in women, whereas mean
LVEFwas higher in view of the lower prevalence of patients
with LVEF less than 30% (Table 1). As for AVR popula-
tions, female TAVI patients showed a lower aortic valve
area, annular diameter, and higher mean and peak gradients1532 The Journal of Thoracic and Cardiovascular Sur(Table 1). No sex-related differences were found in
procedural characteristics, except for a higher use of
Edwards prostheses in women (Table 2).
Impact of Female Sex on AVR Outcome
When periprocedural outcomes after AVR were consid-
ered, female sex proved to be an independent predictor of
risk-adjusted 30-day mortality (OR, 2.34; Table 3), in
view of a higher 30-day mortality compared with men
undergoing surgery (women, 3.7%; vs men, 2.2%;
Table 3). Apart from female sex, concomitant moderate
to severe mitral regurgitation independently predicted
30-day mortality (OR, 2.6; P ¼ .009). About 55% of
women undergoing AVR received transfusions periopera-
tively, compared with 44.1% of men, with 3.4  3.1
units/patient vs 3.7  3.5 units/patient in men (Table 3).
Accordingly, female sex was an independent predictor for
risk-adjusted transfusions during the perioperative course
(OR, 1.47; Table 3). Preoperative hemoglobin level also
significantly affected the perioperative need for transfusions
(OR, 0.71; P ¼ .0001).
On the other hand, no sex-related differences were
recorded in the AVR population in terms of risk-adjusted
permanent AV block, major vascular damage, acute
myocardial infarction, stroke, and cardiogenic shock.
Furthermore, no differences were found between female
and male AVR patients in intensive care unit length of
stay and hospitalization (Table 3). Finally, higher peak
gradients were detected in women after AVR (exponentia-
tion of the beta coefficient, 4.96; Table 3).
Impact of Female Sex on TAVI Outcome
When the TAVI population was considered, female sex
did not impact risk-adjusted 30-day mortality (Table 3).
However, when the 42 deaths recorded in the TAVI popula-
tion were considered, previous aortic interventions andgery c May 2014
TABLE 3. Prevalence of events and risk-adjusted ORs stratified by type of intervention
Outcomes
AVR (N ¼ 1383) n (%) TAVI (N ¼ 725) n (%)
M (N ¼ 768) F (N ¼ 615)
ORadj
(women vs men) P M (N ¼ 297) F (N ¼ 428)
ORadj
(women vs men) P
30-day mortality 17 (2.2) 23 (3.7) 2.34 .043 20 (6.7) 22 (5.1) 0.93 .855
Residual aortic regurgitation
None/mild 760 (99.0) 608 (98.9) 1.04 .941 262 (88.2) 398 (93.0) 0.52 .018
Moderate/severe 8 (1.0) 7 (1.1) 35 (11.8) 30 (7.0)
Permanent AV block 17 (2.2) 16 (2.6) 1.33 .436 51 (17.2) 41 (9.6) 0.61 .050
Major vascular damage 2 (0.3) 0 (0.0) - 8 (2.7) 25 (5.8) 2.92 .018
AMI 6 (0.8) 2 (0.3) 0.37 .238 3 (1.0) 2 (0.5) 0.79 .818
Stroke 10 (1.3) 10 (1.6) 1.19 .717 3 (1.0) 6 (1.4) 1.97 .417
Transfusions 339 (44.1) 337 (54.9) 1.47 .003 79 (26.6) 150 (35.1) 1.93 .003
Number of units* 3.7  3.5 3.4  3.1 0.97 .908 2.8  2.5 2.5  2.5 0.99 .995
Cardiogenic shock 21 (2.7) 16 (2.6) 1.31 3495 8 (2.7) 11 (2.6) 1.18 .769
Hospital stay (days)y 7 6 1.83 .549 7 7 0.84 .793
ICU stay (days)y 2 2 1.33 .230 2 2 0.56 .310
Aortic valve pattern
Peak gradient (mm Hg)* 24.3  10.8 25.8  11.9 4.96 .027 20.1  13.1 20.3  12.8 0.78 .824
Mean gradient (mm Hg)* 13.2  6.7 14.0  7.0 2.29 .054 10.8  7.7 10.8  6.8 1.16 .785
Each end point has been adjusted using factors selected by the stepwise procedures. The variables used to adjust the 30-day mortality ORs were as follows: AVR included the
following: age, diabetes, chronic dialytic treatment, previous vascular surgery, frailty score, critical preoperative state, coronary artery disease, pulmonary hypertension; and TAVI
included the following: age, creatinine level, unstable angina, previous vascular surgery, critical preoperative state, and LVEF. ORadj, Adjusted OR; AMI, acute myocardial
infarction; ICU, intensive care unit; AV, atrioventricular. *Variables presented as mean  standard deviation and exponentiation of the beta coefficient. yPresented as median
values and exponentiation of the beta coefficient.
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Dcritical preoperative state were independent predictors for
risk-adjusted 30-day mortality (OR, 3.7; P ¼ .011; and
OR, 3.5; P ¼ .011, respectively), with only a trend toward
statistical significance for risk-adjusted 30-day mortality
previous aortic valvuloplasty (OR, 2.13; P ¼ .061).
Furthermore, the co-existence of moderate to severe mitral
regurgitation, in contrast with the AVR population, did not
impact 30-day mortality (P ¼ .159).
On the other hand, female sex was an independent
predictor for major vascular damage (OR, 2.92), which
occurred in 5.8% of female compared with 2.7% of TAVI
male patients (Table 3). In addition to female sex, preoper-
ative creatinine level greater than 2 mg/dL proved to
be an independent predictor of major vascular damage
(OR, 3.18; P ¼ .031).
As for AVR patients, female sex also significantly
impacted the need for periprocedural transfusions (35.1%
of female TAVI patients were transfused compared with
26.6% of male TAVI patients; OR, 1.93), with a mean of
2.5 units/patient (Table 3). Major vascular complications
indeed were found as the strongest predictors for periproce-
dural transfusions (OR, 9.7; P¼ .0001), as well as preoper-
ative hemoglobin level (OR, 0.69; P ¼ .0001).
Moderate to severe postprocedural aortic regurgitationwas
less common in female TAVI patients (7.0%; vs men,
11.8%), thus, resulting in female-sex protection against that
complication (OR, 0.52; Table 3). The manufacturer was
shown to affect the earlier-mentionedoutcome, given the pro-
tective effect of theEdwardsLifesciences Sapienvalveversus
the CoreValve toward postprocedural aortic regurgitationThe Journal of Thoracic and Car(OR, 0.61; P ¼ .018). However, the type of TAVI prosthesis
did not impact 30-day mortality or major vascular complica-
tions (OR, 0.60; P ¼ .164; and OR, 0.87; P ¼ .718 for the
Edwards Lifesciences Sapien valve vs the CoreValve,
respectively). A permanent AV block was similarly less
common in female TAVI patients (9.6% vs 17.2%), thus
showing a trend toward significance for female sex as a pro-
tective factor against a post-TAVI AV block (P ¼ .05; OR,
0.61). Finally, female sex did not impact periprocedural
acute myocardial infarction, stroke, cardiogenic shock,
length of intensive care unit stay, hospitalization, and
transprosthetic gradients after TAVI (Table 3).
DISCUSSION
Several conclusions can be drawn by the present analysis
of hospital results after AVR or TAVI in the 2108 patients
enrolled in this prospective multicenter registry: (1) female
sex is characterized by an overall worse risk profile in
the AVR population; (2) female sex carries a different
(not necessarily worse) baseline risk profile in TAVI
candidates; (3) female sex is still an independent risk factor
formortality after AVR; (4) female sex is not a risk factor for
mortality after TAVI but it is an independent predictor for
in-hospital major vascular complications; and (5) women
need more transfusions regardless of the chosen treatment.
Female-Related Differences in Risk Profiles and
Outcome After AVR
Women undergoing AVR in this study showed a signifi-
cantly worse risk profile than men. These data are notdiovascular Surgery c Volume 147, Number 5 1533
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Dnew, given that female sex is a well-known independent risk
factor for surgical mortality in both the EuroSCORE and the
Society of Thoracic Surgeons score (www.euroscore.
org/euroscore_scoring.htm and http://209.220.160.181/
STSWebRiskCalc261/). Although the reasons for these
sex-related differences in risk profiles are far from being
completely understood, the higher prevalence of comorbid
conditions and the older age of women in the majority of
the available studies indicated that female sex behaves as
a proxy-variable more than individual risk factors.9 In
addition, the lower body weight and bovine serum albumin
level of women, as also found in our AVR cohort from the
OBSERVANT registry, and parallel cardiac structures that
are smaller than the corresponding counterparts of men,
thus suggest more technically demanding interventions.9
Furthermore, the lower body mass index of women has
been shown to be a risk factor for mortality, morbidity,
and bleeding after surgery.9 Finally, according to the
demonstration that both NYHA and frailty scores impact
survival after AVR,10,11 and given the higher NYHA and
frailty score of our AVR women, it is not surprising that
female sex was confirmed as an independent risk
factor for mortality in the OBSERVANT registry. Besides
such findings, however, we confirmed here that the
co-existence of moderate to severe mitral regurgitation
also impacted early survival in the surgical cohort, thus
fueling the recent highly debated need for concomitant
mitral surgery during AVR.12
Female sex in AVR patients also proved an independent
predictor of intraprocedural/postprocedural transfusions,
despite the absence of differences in major vascular
complications. The detrimental impact of perioperative
transfusions on outcome in the surgical population has
been well ascertained.13 A recent prospective study on
613 adults undergoing cardiac surgery showed female sex,
together with older age, lower preoperative hemoglobin
levels, lower body surface area, and higher intraoperative
hemodilution, some of which also were prevalent in our
female AVR cohort, as independent predictors of postoper-
ative transfusions.14 Indeed, preoperative hemoglobin level
was an independent predictor for transfusions also in
our OBSERVANT experience. Finally, it should not be
underestimated that aortic valve stenosis is recognized as
a hemodynamic condition whose related shear stress favors
an acquired von Willebrand syndrome, also affecting
platelet function and hemostasis.15 It can be speculated
that a combination of all the earlier mentioned factors might
contribute to the higher rate of transfusions observed in
women undergoing AVR.
Female-Related Differences in Risk Profiles and
Outcome After TAVI
Few studies addressing the role of sex in the TAVI
procedure have been published to date. Hayashida et al,41534 The Journal of Thoracic and Cardiovascular Surin a single-center French registry, showed an overall better
risk profile in women, a finding also confirmed by Humph-
ries et al.5 Buchanan et al,6 in a single-center Italian
experience, similarly showed a higher prevalence of
comorbidities in men undergoing TAVI, although women
had a worse clinical presentation at hospital admission
with a higher NYHA class. Supposedly, the better risk
profile of women in the study by Hayashida et al4 and
Humphries et al5 resulted in their lower mortality and the
consequent recognition of male sex (rather than female as
in the surgical literature) as an independent predictor of
mortality in TAVI, thus supporting the protective effect of
female sex on 1-year mortality identified by the Pivotal
Placement of Aortic Transcatheter (PARTNER) trial cohort
A.1 In our OBSERVANT registry we found a higher
prevalence of comorbid conditions in male TAVI patients,
but a similar EuroSCORE, NYHA class, and frailty score
in men and women. The earlier-mentioned data may
help to understand why TAVI seems to reduce the gender
disparity seen in the AVR population. Despite the higher
prevalence of well-known comorbid conditions affecting
outcome detected in male TAVI patients, other unweighted
risk factors were present in women, thus balancing the
strength of the comorbid conditions, and resulting in similar
EuroSCORE, NYHA class, and frailty scores, the latter
being the real determinants of early mortality. Indeed,
Stortecky et al16 identified several geriatric proxies, overall
assessing the degree of frailty, as better discriminators in the
prediction of hospital mortality. Similarly, Munoz-Garcia
et al,17 in a single-center Spanish registry, confirmed the
Charlson Index and Karnofsky score as better predictors
for hospital mortality than the logistic EuroSCORE. In
addition, it must be considered that TAVI procedures do
not involve the use of cardiopulmonary bypass, thus
removing some of the cardiopulmonary bypass–related
risk factors from the risk profile of women undergoing
TAVI that already have been proven to preferentially affect
women rather than men during AVR (eg, hemodilution).18
Our findings therefore confirmed the comparable mortality
of men and women after TAVI seen by Buchanan et al6 in
a cohort with a similar risk profile to our population, and
also confirm another recent multicenter Italian experience
in patients undergoing implantation of CoreValve only
that similarly showed comparable baseline comorbidities
and similar hospital survival between sexes.19 However,
although it is interesting to note that the type of
TAVI prosthesis (Edwards Lifesciences Sapien valve vs
CoreValve) did not affect mortality in our experience,
determinants of hospital death after TAVI were previous
aortic interventions (with a trend also for previous aortic
valvuloplasty) and critical preoperative state, the former
possibly underscoring the critical role for adequate
preoperative planning, and the latter emphasizing the
importance of correct indications.gery c May 2014
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dent predictor for major vascular complications. It has been
reported that major vascular complications increased the
risk for midterm mortality 2-fold.4 Another study showed
that major and minor vascular complications occur in as
high as 10.7% and 11.5%, respectively, of the TAVI
population, with rates of life-threatening bleeding, major
bleeding, and red blood cell transfusions of 13.9%,
20.9%, and 38.9%, respectively.20 Buchanan et al6 reported
a trend for women of developing more major vascular
complications. Humphries et al5 similarly reported a higher
incidence of major vascular complications and major/
life-threatening bleeds in women. As in our study, in
a multicenter European experience Van Mieghem et al21
showed female sex as an independent predictor (together
with peripheral arterial disease, learning curve, and
percutaneous access strategy) for both major vascular
complications and life-threatening/disabling bleeding. It is
noteworthy that preoperative renal damage (creatinine level
> 2 mg/dL) significantly impacted the risk of major
vascular complications in OBSERVANT registry that
outcome (OR, 3.18), thus suggesting, as in the Van
Mieghem et al21 study, a pivotal role for severe and calcified
atherosclerosis in the genesis of periprocedural vascular
complications. As for mortality, it is also worth noting
that the type of TAVI prosthesis did not impact vascular
complications. Certainly more studies and future analyses
are needed to better understand this issue.
Similar to our AVR population, female sex proved to
be an independent predictor for transfusions also in
our TAVI population, thus confirming previous studies
showing a higher transfusion rate in women.6 Periope-
rative transfusions after TAVI affect outcome as in
cardiac surgery: a single-center French study showed
that transfusions of 4 or more units/patient augment
1-year mortality by 4.66-fold.4 Similarly, the recent
Pooled Rotterdam-Milano-Touluse In Collaboration
(PRAGMATIC) Plus initiative showed that bleeding
was frequent after TAVI and mainly driven by vascular
complications, and that red packed cell transfusions
were associated with increased 1-year mortality and an
increased risk of major stroke and acute kidney injury.20
Although female TAVI patients in our registry had
lower preoperative hemoglobin levels than their male
counterparts, which also partly explains that result,
they, however, had higher major vascular complications.
As for the PRAGMATIC Plus study, we confirmed here
that major vascular complications were the most impor-
tant factors impacting the need for transfusions: our
data thus underscore the need for multidisciplinary efforts
to reduce periprocedural vascular complications.
Despite finding a lower body weight and lower annular
diameter in female TAVI patients, as already reported by
both Hayashida et al4 and Buchanan et al,6 we alsoThe Journal of Thoracic and Carconfirmed a similar hemodynamic profile of TAVI prosthe-
ses in women and men in terms of comparable peak and
mean gradients after risk adjustment (Table 3). On the other
hand, female sex was a protective factor in the TAVI
population against moderate to severe aortic regurgitation,
and also showed a protective trend against the need for
a permanent pacemaker. Unbehaun et al22 already reported
male sex as a predictor of post-TAVI paravalvular leakage,
underscoring the direct relation between sex, annular
dimensions, and paravalvular leakage after TAVI, and
further showing the beneficial effect of oversizing of
TAVI in women to reduce the risk of postprocedural
regurgitation. The protective effect of the Edwards Life-
sciences Sapien valve against postprocedural moderate to
severe aortic regurgitation, as found in the OBSERVANT
registry, also was noteworthy. This finding already has
been suggested in the literature,22 and was addressed specif-
ically by Nombela-Franco23 in a recent study comparing the
hemodynamic performances of self-expandable versus
balloon-expandable TAVI prostheses.
When the postprocedural need for a permanent pace-
maker was considered, our findings confirmed previous
literature studies showing fewer pacemaker implantations
in women,19 which possibly also was related to the lower
rate of CoreValve implantations in our female TAVI
patients.24
Finally, we reported a lower rate of early stroke in both
AVR and TAVI patients compared, for example, with that
reported in the PARTNER A trial, although we did not
show sex-related differences for stroke in both populations
as in the PARTNER A trial.25 OBSERVANT was an
observational registry mirroring the real world practice
of all-comers in current Italian practice, whereas the
PARTNERTrial was a prospective randomized study aimed
at the direct comparison between the 2 procedures.25 Indeed,
our results also agree with a recent meta-analysis on more
than 10,000 published patients, reporting a stroke incidence
of 1% to 3% in the first 30 postoperative days.26 Further-
more, other published nonrandomized studies specifically
focused on the role of sex reported a stroke incidence
comparable with OBSERVANT results.4,6 Moreover,
literature data showed the importance of preoperative
peripheral arteriopathy, porcelain aorta, and history of
stroke (whose prevalence was relatively low in the
OBSERVANT population) in favoring postprocedural
cerebrovascular events.27 However, the present study was
not targeted for perioperative stroke, although future
investigations are needed to better assess the prognostic
factors and the impact on outcome of this life-threatening
complication.
In conclusion, our prospective multicenter registry
confirms that female sex is still a risk factor for hospital
mortality after AVR, for in-hospital major vascular
complications after TAVI, and for transfusions duringdiovascular Surgery c Volume 147, Number 5 1535
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to some extent the different baseline risk profile of women
in the 2 populations. Tremendous efforts should be made
by surgeons, cardiologists, and anesthesiologists in the
near future to significantly decrease major periprocedural
complications and transfusion rates. The different hemody-
namic behavior of AVR and TAVI in female patients
early after the procedure, together with their impact on
ventricular remodeling and on mid- to long-term follow-
up evaluation, deserves future investigations.
Study Limitations
Evaluating the impact of a specific treatment by using
a registry can lead to incorrect conclusions because of the
influence of unassessed confounding variables. In this
study, treatment was not assigned randomly but was as-
signed after the evaluation of a multidisciplinary local heart
team, as suggested by current guidelines,8 although this
policy still might have generated an unavoidable risk
for bias regarding treatment selection. No standardized
protocols for cardiopulmonary bypass and anesthetic
techniques were used.7 No specific recommendation or
protocols exist on perioperative transfusions,7 therefore,
our results showing a different transfusion rate between
male and female patients might have been biased by other
variables that were not included. However, details on
preoperative stratification, treatment allocation, techniques
used (surgery or TAVI, transfemoral vs nontransfemoral
routes, choice of surgical and percutaneous valves, and so
forth), definition of outcome variables, postprocedural
medical management, data management, quality control
of registry, and so forth, all have been detailed previously.7
On the other hand, results coming from registries are
considered the real-world mirror of current practice. These
strengths and limitations stem from the observational nature
of the OBSERVANT study, which is a mirror of the current
Italian clinical practice. For any observational study/regis-
try, no standardization is planned a priori by definition;
similarly, for any observational study, no quality measure-
ment between centers at different volumes, historical
results, skills, and so forth were considered as end points,
although they were considered in the multivariate analyses.
Furthermore, all end points were risk adjusted for all the
collected variables by means of univariate and multivariate
models; again, uncollected variables, as for any study of this
type, potentially may have affected the results of these
models.
Another important limitation was that outcomes were
not defined according to the Valve Academic Research
Consortium. This mainly was because the data collection
began before the publication of the Valve Academic
Research Consortium criteria. Another reason was that
those definitions were designed specifically to define
complications after TAVI, therefore they may be misleading1536 The Journal of Thoracic and Cardiovascular Surto illustrate complications after AVR, likely resulting in
their overestimation. The incompleteness of enrollment at
the time of this writing may have limited the conclusions.
Finally, the study was not targeted to compare women
undergoing AVR with those undergoing TAVI; therefore,
no comparison between the 2 procedures are provided
here. However, the results of this study, as well as the
absence in the current literature of comparisons between
AVR and TAVI in female patients, emphasize the urgent
need for outcome results after TAVI and AVR in this
particular subset of patients.
The authors thank all Italian cardiac surgeons, interventional
cardiologists, and anesthesiologists dealing with TAVI and AVR
procedures, as well as those who collected data (Appendix 1).
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OBSERVANT Research Group
Study Coordination was performed by the following
members: Fulvia Seccareccia, Paola D’Errigo, Stefano Ro-
sato, Alice Maraschini, Gabriella Badoni.
National Centre for Epidemiology, Surveillance and
Health Promotion, Italian National Institute of Health,
Roma.
Steering Committee was composed of the following
members: Fulvia Seccareccia, Paola D’Errigo, Stefano Ro-
sato, Italian National Institute of Health, Roma; Corrado
Tamburino, SICI-GISE, Catania, Gennaro Santoro, FIC,
ANMCO, Firenze; Francesco Santini, SICCH, Verona;
Claudio Grossi, SICCH, Cuneo; Marco Ranucci, ITACTA,
S. Donato Milanese, MI; Remo Daniel Covello, ITACTA,
Milano; Danilo Fusco, Epidemiology Department, Lazio
Region, Roma; Rossana De Palma, Emilia Romagna
Region; Salvatore Scondotto, Sicilia Region.
Executive Working Group was composed of the follow-
ing members: Corrado Tamburino, Marco Barbanti, SICI-
GISE, Catania; Francesco Santini, Francesco Onorati,
SICCH, Verona; Gennaro Santoro, FIC, ANMCO, Firenze;
Marco Ranucci, ITACTA, S. Donato Milanese, MI; and
Remo Daniel Covello, ITACTA, Milano.
Regional Cooperations were performed by the following:
Anna Orlando, Piemonte; Francesco Copello, Liguria; Lo-
ris Zanier, Friuli VG; Carlo Zocchetti, Lombardia; Mario
Cecchi, Toscana; Piero Borgia, Lazio; Egidio Celentano,
Campania; Aldo Mauro, Calabria; Giovanni De Luca,
Fausto Marchetta, Sicilia; and Antonello Antonelli, Ro-
sanna Porcu, Sardegna.
Participating hemodynamic centers were as follows:
AOUMolinette, San Giovanni Battista di Torino, Torino,
S. Marra and M. D’Amico.
AOUMolinette, San Giovanni Battista di Torino, Torino,
F. Gaita and C. Moretti.
Ospedale Mauriziano ‘‘Umberto I’’, Torino, M. De Ben-
edictis and T. Aranzulla.
AO Nazionale Ss. Antonio e Biagio e Cesare Arrigo,
Alessandria, G. Pistis and M. Reale.
Istituto Clinico S. Ambrogio, Milano, F. Bedogni and N.
Brambilla.
Fondazione San Raffaele del Monte Tabor, Milano, A.
Colombo, A. Chieffo, and A. Ferrari.
IRCCS Policlinico San Donato, San Donato M.se (MI),
L. Inglese and F. Casilli.
Spedali Civili di Brescia, Universita, Brescia, F. Ettori
and M. Frontini.
Ospedale Luigi Sacco, AO, Polo Universitario, Milano,
C. Antona and E. Piccaluga.1538 The Journal of Thoracic and Cardiovascular SurAO Ospedale Niguarda Ca Granda, Milano, S.
Klugmann and F. De Marco.
AO Bolognini Seriate, Seriate (BG), M. Tespili and A.
Saino.
Ospedale ‘‘S. Maria di Ca’ Foncello,’’ Treviso, E. Fran-
ceschini Grisolia.
AO di Padova, Padova, G. Isabella and C. Fraccaro.
AOU Santa Maria Della Misericordia di Udine, Udine,
A. Proclemer, T. Bisceglia, and I. Armellini.
AOU San Martino, Genova, M. Vischi and E. Parodi.
AOU Pisana, Pisa, S. Petronio and C. Giannini.
AOU Senese Le Scotte, Siena, C. Pierli and A. Iadanza.
AOU Careggi, Firenze, G. Santoro and F. Meucci.
European Hospital, Roma, F. Tomai and A. Ghini.
Policlinico Umberto I, Roma, G. Sardella and M.
Mancone.
AOU Integrata Verona, Verona, F. Ribichini, C.
Vassanelli, and R. Dandale.
AOOORRS Giovanni di Dio e Ruggi d‘Aragona, AOU di
Salerno, Salerno, P. Giudice and F. Vigorito.
AOU Consorziale Policlinico di Bari, Bari, A. Bortone,
L. De Luca Tupputi Schinosa, and E. De Cillis.
AOU Mater Domini, Catanzaro, C. Indolfi and C.
Spaccarotella.
ARNAS Ospedale Civico, Di Cristina, Benfratelli,
Palermo, A. Stabile and C. Gandolfo.
AOU Policlinico, Vittorio Emanuele, Ospedale Ferrar-
otto, Catania, C. Tamburino and G. Ussia.
Participating cardiac surgery centers were as follows:
AOUMolinette, San Giovanni Battista di Torino, Torino,
M. Rinaldi and S. Salizzoni.
AOS Croce e Carle, Cuneo, C. Grossi and O. Di
Gregorio.
AO Nazionale Ss. Antonio e Biagio e Cesare Arrigo,
Alessandria, P. Scoti and R. Costa.
OspedaleMauriziano ‘‘Umberto I,’’ Torino, R. Casabona
and S. Del Ponte.
Istituto Clinico S. Ambrogio, Milano, P. Panisi and G.
Spira.
Fondazione Poliambulanza Istituto Ospedaliero,
Brescia, G. Troise and A. Messina.
Fondazione IRCSS Policlinico San Matteo, Pavia, M.
Vigano and M. Aiello.
Fondazione San Raffaele del Monte Tabor, Milano, O.
Alfieri and P. Denti.gery c May 2014
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DIRCCS Policlinico San Donato, San Donato M.se (MI),
L. Menicanti and B. Agnelli.
Spedali Civili di Brescia, Universita, Brescia, C.
Muneretto and M. Frontini.
Spedali Civili di Brescia, Universita, Brescia, M.
Rambaldini and M. Frontini.
AO Ospedale di Lecco, Presidio Alessandro Manzoni,
Lecco, A. Gamba and G., Tasca.
Ospedali Riuniti di Bergamo, AO, Bergamo, P. Ferrazzi
and A. Terzi.
Ospedale Luigi Sacco, AO, Polo Universitario, Milano,
C. Antona and G. Gelpi.
AOOspedale Niguarda Ca Granda,Milano, L.Martinelli
and G. Bruschi.
Presidio Ospedaliero S.Chiara, Ospedale di Trento,
Trento, A. C. Graffigna.
AOU Integrata Verona, Verona, A. Mazzucco.
AOU Ospedali Riuniti di Trieste, Ospedale di Cattinara,
Trieste, A. Pappalardo and G. Gatti.
AOU Santa Maria Della Misericordia di Udine, Udine,
U. Livi and E. Pompei.
AOU San Martino, Genova, G. Passerone and E. Parodi.
AOU Pisana, Pisa, U. Bortolotti and S. Pratali.
AOU Careggi, Firenze, P. Stefano and C. Blanzola.
Ospedale del Cuore G. Pasquinucci, Montepepe (MS),
M. Glauber, A. Cerillo, and F. Chiaramonti.
AO Santa Maria, Terni, A. Pardini and F. Fioriello.
AOGM Lancisi, Ancona, L. Torracca and G. Rescigno.
European Hospital, Roma, R. De Paulis and S. Nardella.
AOS Camillo-Forlanini, Roma, F. Musumeci and
G. Luzi.The Journal of Thoracic and CarPoliclinico Gemelli, Roma, G. Possati and G. Bonalumi.
Universita Campus Bio-Medico di Roma, Roma,
E. Covino and F. Pollari.
AO Sant’Andrea, Roma, R. Sinatra and A. Roscitano.
Policlinico Tor Vergata, Roma, L. Chiariello and
P. Nardi.
Clinica San Michele, Maddaloni (CS), T. Lonobile and
F. Baldascino.
AOOORRS Giovanni di Dio e Ruggi d‘Aragona, AOU di
Salerno, Salerno, G. Di Benedetto and G. Mastrogio-
vanni.
AO San Sebastiano, Caserta, L. Piazza and J. Marmo.
AOU Federico II, Napoli, C. Vosa and V. De Amicis.
Azienda Sanitaria Locale Le Fazzi Presidio Ospedaliero
Vito Fazzi, Lecce, M. Villani and M. A. Pano.
S. Anna Hospital, Catanzaro, M. Cassese and
A. Antonazzo.
Centro Cuore Morgagni, Pedara (CT), L. Patane, M.
Gentile, and S. Tribastone.
ARNAS Ospedale Civico, Di Cristina, Benfratelli,
Palermo, F. Follis and G. Montalbano.
ISMETT (Istituto Mediterraneo per i Trapianti e Terapie
ad Alta Specializzazione), Palermo, M. Pilato and V.
Stringi.
AO Ospedali Riuniti Papardo, Piemonte, Messina, F.
Patane and G. Salamone.
AOU Policlinico Paolo Giaccone, Palermo, G. Ruvolo
and C. Pisano.
AOU Policlinico, Vittorio Emanuele, Ospedale Ferrar-
otto, Catania, C. Mignosa and A. Bivona.
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